Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
-
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
-
BUSINESS Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
-
BUSINESS Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
-
COMMENTARY New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
-
REGULATORY MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
-
BUSINESS Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People
May 1, 2025
-
BUSINESS Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
-
BUSINESS Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
BUSINESS Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
-
REGULATORY GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
-
REGULATORY MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
-
BUSINESS Investments Follow Where Innovation Is Valued, Says Novartis Japan Chief
April 18, 2025
-
BUSINESS Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
-
BUSINESS Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
-
REGULATORY MHLW to Revise Patent Linkage Scheme in FY2025, Create Expert Committee
April 16, 2025
-
BUSINESS Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…